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Background:Heart failure (HF) and chronic obstructive pulmonary disease (COPD) share a common organ failure
trajectorymarked by prognostic uncertainty,which is a barrier to appropriate provision of palliative care.Wede-
scribe in a prospective cohort from specialist hospital services the epidemiology and late clinical course of these
chronic diseases to trace criteria for transition to palliative care in the community.
Methods and results: Seven centers enrolled 267 patients with advanced HF (n = 174) or COPD (n = 93) using
common (multiple hospitalizations or severely impaired functional status or cachexia) and disease-speciﬁc
(HF: systolic dysfunction, NYHA classes III–IV, end-organ hypoperfusion; COPD: very severe airﬂow obstruction,
hypoxemia, hypercapnia, or long-term oxygen therapy) entry criteria. These patients represented 7.2% and 13%
respectively of the overall HF and COPD population hospitalized during one year. They showed similar symptom
burden, functional and quality of life impairment, recurrent hospitalizations, and 6-month mortality (39% and
37%, respectively). Organ failure progression was the cause of death in N75%. In-hospital overall stay during
the previous year was the main mortality predictor in both. Disease-speciﬁc predictors included anemia,
hyponatremia, no beta-blockers in HF; older age, hypercapnia in COPD.
Conclusions: Patients with advancedHF/COPD represent almost 10% of subjects hospitalized yearlywith a prima-
ry diagnosis of HF or COPD, have similarly impaired functional status, disabling symptoms and reduced survival.
Overall days spent in-hospital during the previous year, a “red ﬂag” in the late clinical course of both diseases,
might be used as a simple, reliable screening tool for appropriate transition to palliative care in the community.© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).f Health Grant RF-MAR-2007-
tion, analysis and interpretation
bmit the article for publication.
erca, Azienda Ospedaliera Papa
24127 Bergamo (BG), Italy.
eliability and freedom from bias
land Ltd. This is an open access articl1. Introduction
Heart failure (HF) and chronic obstructive pulmonary disease (COPD)
are systemic disorders with potentially overlapping pathophysiological
process [1] and represent global epidemics [2,3]. Both are chronic debili-
tating conditions and incur signiﬁcant morbidity and mortality. Their
natural history is typical of the organ failure trajectory [4], with symptom
burden and functional impairment comparable to advanced cancer [5–7],
but frustrating prognostic uncertainty [8,9]. Outcome assessment is chal-
lenging and relatively unpredictable in individuals [9–14], particularly ine under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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marked by heavy use of health services and more common aggressive
treatment than in comparably end-stage malignant disease [18,19]. The
more linear decline of patients with advanced cancer has traditionally
been the model to approach end-stage disease, when decisions on life-
prolonging treatment should be considered. Organ specialist physicians,
such as cardiologists and pulmonologists, are traditionally treatment-
focused and may lack the symptommanagement perspective, which be-
comes increasingly meaningful to patients as they progress to end-stage.
A better understanding of the late clinical course of organ failure
conditions, such as HF and COPD, helps calibrate expectations, guide
communication, and inform rational decisions which may beneﬁt pa-
tients and their families. The importance of a palliative care approach,
as a key component of management in advanced disease, has been
highlighted in recent scientiﬁc society statements [20–23]. Further-
more, a palliative approach integrating standard care should decrease
the hospitalization rate of these very ill patients, improving patients'
quality of life and diminishing the economic burden of the disease.
Palliative care in Italy has recently developed to improve standards
for oncological diseases, but still few patients with non-malignant dis-
ease access the network [24]. Furthermore national criteria for referral
of patients with HF or COPD to palliative care services by general prac-
titioners or organ specialists have not yet been deﬁned. Under this ratio-
nale, the study was funded by the Italian Health Ministry (Grant RF-
MAR-2007-679550) in a call devoted to research on health services
organization.
We set-up a multicenter observational registry of patients with HF
and COPD accessing hospital care in order to 1) deﬁne the proportion
of subjects who access hospital care meeting criteria for advanced
disease, 2) compare the late clinical course of advanced HF or COPD,
expressed as symptom burden, functional status, quality of life, recur-
rent hospitalization andmortality, and 3) identify, as support to nation-
al initiatives directed at organizing the provision of health care services,
patient characteristics associated with a mid-term negative outcome,
for whom transition to targeted palliative interventions in the commu-
nity, may be warranted.
2. Methods
2.1. Participants
From March 2010 till March 2012, patients with HF or COPD were
identiﬁed at 7 enrolling sites from the cardiology or pulmonology out-
patient clinics and from institutional hospital discharge databases
using International Classiﬁcation of Disease 9 primary diagnosis codes
forHF and COPD. Patients' clinical recordswere reviewed at each center.
2.2. Eligibility criteria
We enrolled in an observational registry consecutive patients
meeting the following general eligibility criteria, valid for both HF
and COPD: ≥2 hospital admissions for the index diagnosis within
the previous 12 months; in patients with b2 admissions, an overall
length of stay N 40 days (twice the threshold value set by the Italian
Ministry of Health as abnormal length of stay for reimbursement
criteria) as a clue to difﬁculties in stabilizing the patient was required
as an alternative criterion, OR Karnofsky performance status b 50 or
dependent in 3 or more basic activities of daily living, OR cachexia, de-
ﬁned as unintentional loss of N10% body weight within the previous
12 months [25], or a body mass index b 21 kg/m2 [26] and serum
albumin b 2.5 g/dL as supportive criterion.
In addition to the general criteria, the following disease-speciﬁc
criteria had to be fulﬁlled:
- Patients with HF had to show severely depressed pump function
(left ventricular ejection fraction b 30% or b40% with moderateto severe mitral insufﬁciency), New York Heart Association
(NYHA) functional classes III–IV dyspnea, clinical or laboratory
signs of end organ hypoperfusion, including glomerular ﬁltration
rate b 60ml/min, sodium b 135mEq/L, hemoglobin b 11 g/dL, and
total bilirubin N 1.2 mg/dL.
- Patients with COPD had to show very severe airﬂow obstruction
(Forced Expiratory Volume in 1 s [FEV1] b 30%), or hypoxemia
(PaO2 b 55 mm Hg), or hypercapnia (PaCO2 N 45 mm Hg, i.e. above
the upper normalcy threshold), OR to be on long-term oxygen
therapy N 8 h/day.
2.3. Measurements
Patients were recalled for an outpatient visit to conﬁrm eligibility.
The diagnosis of HF or COPD was based on the European Society of Car-
diology [3] or Global Initiative for Chronic Obstructive Lung Disease [2],
respectively. Demographics, clinical and laboratory data were recorded.
Comorbidities were assessed by history and chart review. Patients were
then questioned about their current symptoms. Dyspnea was graded
from 1 (none) to 5 (too breathless to leave the house) using theMedical
Research Council Scale [27]. Pain intensity was measured using the
Visual Analogue Scale for Pain (VAS Pain) [28].
Cognitive impairmentwas screened by TheMiniMental State Exam-
ination using a cut-off threshold of b24 [29]. Functional status was
assessed by the Karnofsky Performance Status Scale [30] and Basic
Activities of Daily Living [31]. Quality of life was assessed through the
following generic and disease-speciﬁc validated tools: SF12, a shortened
version of the Short Form 36 of theMedical Outcomes Study [32] for all,
plus the Minnesota Living with Heart Failure for HF [33], and the Air-
ways Questionnaire 20 for COPD [34].
Whenever feasible, to quantitatively assess their functional perfor-
mance, patients underwent a single six-minute walking test using the
American Thoracic Society criteria [35]; the total distancewalked inme-
ters was recorded to assess functional impairment and expressed as
percent of predicted values [36].
For COPD patients, the composite Bodymass index, airﬂowObstruc-
tion, Dyspnea, and Exercise capacity (BODE) index [14] was calculated.
On June 30, 2012, vital status andmode of death and hospital admis-
sions were ascertained through telephone interview with patients or
caregivers and review of hospital records.
The study protocol conforms to the ethical guidelines of the 1975
Declaration of Helsinki as reﬂected in a priori approval of the Ethics
Committee of each participating institution. Patients gave their written
informed consent to participate.
2.4. Statistical analysis
Categorical variables are presented as frequency percent and contin-
uous variables as mean ± standard deviation or median [interquartile
range]. Between-group differences were tested by chi-square test and
Student's t-test or non-parametric tests according to normal or non-
normal variable distribution.
Kaplan–Meier survival analysis was used to examine the association
between COPD and HF, or both coexisting conditions, and all-cause
mortality. The validity of constant incidence ratios over the follow-up
was checked usingNelson–Aalen cumulative hazard estimates. Coxpro-
portional hazards analysis was used to calculate the adjusted relative
hazards of death by each considered variable [37], which were selected
according to p b 0.10, 20% change of the hazards ratios of other signiﬁ-
cant variables, missing data b 30% of the sample, age, gender and body
mass index were included a priori. Schoenfeld's test was performed to
check the validity of proportional hazards assumption.
A p value of b0.05 was considered signiﬁcant for all analyses, which
were performed using STATA 10.1 (Stata Corporation, College Station,
554 A. Gavazzi et al. / International Journal of Cardiology 184 (2015) 552–558TX, USA, 2007). Reporting of the study conforms with STROBE, along
with references to STROBE and the broader EQUATOR guidelines [38].
3. Results
The study cohort included 267 patients, 174 with advanced HF and
93 with COPD, which represented 7.2% and 13%, respectively, of the
overall HF and COPD population hospitalized during one year, as identi-
ﬁed by the International Classiﬁcation of Disease codes from discharge
database. Baseline characteristics are reported in Table 1.
3.1. Demographic and clinical characteristics
Both groups had a signiﬁcant burden of associated medical condi-
tions, but HF patients, although younger, had on average a signiﬁcantly
higher number of comorbidities than COPD patients. Comorbid COPD
was found in one out of four HF patients. Overall 54% and 36% respec-
tively had spent over 40 days in the hospital (p = 0.009).
Both populations complained of troubling symptoms. Dyspnea, the
most recurrent, was more common and severe in COPD patients, as
demonstrated by a higher proportion of patients who were home-
bound for dyspnea (p= 0.041). Severe fatigue, anorexia and moderate
to severe pain were equally present in both groups, while upper gastro-
intestinal symptoms occurred more frequently in HF patients (p =
0.002). Moreover, 90% of study patients were unable to work and one
third were unable to perform 3 or more basic activities of daily living
(Fig. 1). Cognitive impairment was common and overall one third hadTable 1
Baseline characteristics of the study population.
Characteristics Heart failure (n = 174)
Age (years) 72 ± 12
Male gender (%) 73
Days spent in hospital within 12 months (n) 41 ± 34
Body mass index (kg/m2) 25 ± 5 (n = 158)
Body mass index ≤ 21 kg/m2 (%) 18 (n = 158)
Weight loss N 10% within 12 months (%) 7
Cachexia any of 3 criteria (%) 19
Comorbidities
Comorbidities number 4 ± 1.8
History of hypertension (%) 54
Diabetes and target organ damage (%) 20
Liver dysfunction (%) 17
COPD (%) 26
Ischemic heart disease (%) 79
Anemia (Hemoglobin b 11 g/dL) (%) 34
Chronic kidney dysfunction (%) 42
Peripheral vessel disease (%) 33
Cerebrovascular disease (%) 16
Obstructive sleep apnoea syndrome (%) 11
Atrial ﬁbrillation (%) 30
Cognitive impairment (MMSE b 24) (%) 39 (n = 101)
MMSE 24.4 ± 5
Symptoms
Dyspnea MRC class 4 (home-bound) (%) 23
Severe fatigue (%) 23
Anorexia (%) 58
Upper gastrointestinal symptoms (%) 47
Moderate to severe pain (VAS ≥ 4/10) % 52
Functional capacity
Basic activities of daily living 4.1 ± 2.2 (n = 120)
Karnofsky performance status 50.4 ± 17
Six minutes walking distance (% predicted) 44 ± 77
Laboratory data
Glomerular ﬁltration rate (ml/min/1.73 m2) 48 ± 25
Urea (mg/dl) 94 ± 66
Albumin (mg/dl) 3.45 ± 0.7
Albumin b 2.5 mg/dl (%) 5.0 (n = 141)
Total bilirubin (mg/dl) 1.24 ± 1
Sodium (mEq/l) 138 ± 4
Hemoglobin (g/dL) 11.9 ± 1.8
Data are expressed as number (percentage) or mean ± SD. MMSE, Mini Mental State Examinaa score below the threshold cut-off for the clinical diagnosis of demen-
tia, with a higher prevalence among HF patients. Multi-organ failure
was evident from laboratory data in both groups, butwith a signiﬁcantly
more prominent kidney dysfunction and anemia in HF patients. A
marked reduction in the distance walked at the six-minute walking
test in comparison to reference normal values was recorded in both
groups (Table 1).
Quality of life was poor: perceptions of physical functioning were
universally below the 25th percentile of the age and gender-matched
general population, but also mental health was severely affected in
over 70% of cases (Fig. 1).
Among HF patients (Table 2), pump function was severely de-
pressed and elevated natriuretic peptides indicated persistent conges-
tion. Forty-seven percent of patients had a cardioverter deﬁbrillator
implanted and 39% had undergone cardiac resynchronization therapy.
High dose furosemidewas prescribed in most patients to relieve persis-
tent congestion. Rates of renin–angiotensin system inhibitors and min-
eralocorticoid receptor antagonists treatment were relatively low, in
keeping with the prevalence of kidney dysfunction. Conversely, pre-
scription of beta-blockers, a cornerstone of HF therapy, was high, and
heart ratewas accordinglywell controlled, despite neurohormonal acti-
vation. About one third of patients were on intermittent or continuous
inotropic support.
Among COPD patients (Table 2), the average BODE index, a compos-
ite score that takes into account both airways' ﬂow limitation and the
systemic effects of COPD, was 10, indicating severe multidimensional
impairment and 88% were on long-term oxygen therapy.Chronic obstructive pulmonary disease (n = 93) p value
75 ± 9 0.08
67 0.323
48 ± 35 0.097
27 ± 6 0.31
16 0.86
9 0.615
29 0.085
3.6 ± 1.6 0.037
57 0.699
11 0.083
5 0.007
– –
36 0.0001
17 0.004
13 0.0001
13 0.0001
13 0.590
39 0.007
6 0.0001
21 (n = 73) 0.13
25.6 ± 4 0.082
39 0.041
23 1
52 0.369
27 0.002
56 0.567
3.7 ± 2.0 0.16
49.8 ± 14 0.778
37 ± 29 0.05
66 ± 32 0.0001
65 ± 41 (n = 80) 0.0001
3.22 ± 0.7 0.013
3.4 (n = 88) 0.745
1.18 ± 1 0.691
140 ± 3 0.13
12.2 ± 1.7 0.238
tion; MRC, Medical Research Council; VAS, Visual Analogue Scale.
Fig. 1. Proportion of patients with≤3 preserved basic activities of daily living (BADL), activity levels, SF12mental (MCS) and physical (PCS) components b 25th percentile of the age and
gender-matched general population (n = 179), among heart failure (HF, dark boxes) and chronic obstructive pulmonary disease (COPD, empty boxes) patients.
Table 2
Disease-speciﬁc clinical characteristics.
Heart failure patients N = 174
Ischaemic etiology (%) 77
Systolic blood pressure (mm Hg) 118 ± 22
Heart rate (bpm) 76 ± 14
Left ventricular ejection fraction (%) 26 ± 5
Left bundle branch block (%) 37
Implantable cardioverter deﬁbrillator (%) 49
Cardiac resynchronization therapy (%) 37
Furosemide dose (median [Interquartile range]) (mg) 125 [137]
Spironolactone (%) 51
ACE-inhibitors or ARBs (%) 57
Beta-blockers (%) 74
Digoxin (%) 27
Oral anticoagulant agents (%) 53
Inotropes (%) 32
NTproBNP (median [Interquartile range]) (pg/ml) 2617 [3724]
BNP (median [Interquartile range]) (ng/ml) 639 [1242]
Quality of life MLHFQ (n = 82) total score 49 ± 20
MLHFQ physical dimension 22 ± 9
MLHFQ emotional dimension 10 ± 7
Chronic obstructive pulmonary disease patients N = 93
BODE index 10 ± 3
Oxygen saturation (%) 93 ± 4
PaO2 (mm Hg) 67 ± 15
PaCO2 (mm Hg) 50 ± 13
Forced expiratory volume in 1 s (% of predicted) 45 ± 11
Furosemide (mg/day)* 50 [100]
Oral corticosteroids (%) 54
Inhaled corticosteroids (%) 97
Long acting beta agonists (%) 95
Long acting muscarinic antagonists (%) 87
Hours of oxygen therapy/day (n) 17 ± 10
Long-term oxygen therapy ≤ 15 h/day (%) 29
Long-term oxygen therapy N 15 h/day (%) 59
Non-invasive ventilation (%) 19
Quality of life: Airways Questionnaire-20 score (n = 62) 16 ± 3
Data are expressed as frequency % of patients or mean ± SD or * Median [Interquartile
range].
ACE, Angiotensin Converting Enzyme; ARBs, Angiotensin Receptor Blockers; BODE, Body
mass index, airﬂow Obstruction, Dyspnea, and Exercise capacity; BNP, Brain Natriuretic
Peptide; MLHFQ, Minnesota Living with Heart Failure Questionnaire; NtproBNP, N termi-
nal pro-brain natriuretic peptide.
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quently cachexia (38.6%) than those with either HF (19%) or COPD
(26.9%) alone (p= 0.033). No differences were found in Basic Activities
of Daily Living, Karnofsky performance status and MiniMental Status
Examination score among the 3 groups.3.2. Outcome
During a mean follow-up of 6 ± 4 months, 39% of HF and 37% of
COPD patients died. Survival by Kaplan–Meier analysis (Fig. 2) was sim-
ilar in the two groups (log rank test p=0.58),with amortality rate near
to 40% at 6 months. The incidence of sudden death was low (15% in HF
and 6% in COPD),while themost common cause of demisewas progres-
sion of pump failure in HF (83%) and respiratory failure in COPD (74%).
In both groups hospital readmissions during follow-up were frequent
(60% of HF and 49% of COPD patients were hospitalized at least once)
and length of stay was prolonged, with a median of 30 [interquartileCOPD
HF
HF + COPD
Fig. 2. Kaplan–Meier survival curves of patients with heart failure (dotted line), chronic
obstructive pulmonary disease (continuous line), or coexistent heart failure and chronic
obstructive pulmonary disease (hatched line) enrolled in the registry.
556 A. Gavazzi et al. / International Journal of Cardiology 184 (2015) 552–558range 56] days in HF and 27 [interquartile range 49] days in COPD (p=
0.599).
Six-month mortality was 31% for coexistent COPD and HF vs 37% for
HF and 41% for COPD, but patients with both HF and COPD were admit-
tedmore frequently during follow-up (mean admission number 1.91 vs
1.31 for HF, and 0.87 for COPD; p = 0.003).
None of the patients at the time of recruitment was in a palliative
care program, nor were speciﬁc provisions taken within the protocol
for referral to specialist palliative care.
3.3. Prognostic stratiﬁcation
To assess independent predictors of all-cause mortality the follow-
ing variables were entered in multivariable Cox proportional hazards
models (Table 3): age, gender, body mass index, Medical Reasearch
Council dyspnea scale, number of comorbidities, Karnofsky perfor-
mance status, and overall days in hospital during previous year for the
whole cohort, with the addition of hemoglobin, beta-blockers, and sodi-
um for HF patients, and PaCO2, BODE index, and long-term oxygen ther-
apy for COPD patients. Overall, only the sum of days spent in hospital in
the previous yearwas independently associatedwith outcome,whereas
Karnofsky performance status reached borderline signiﬁcance. In theHF
cohort, lower hemoglobin and sodium levels and lack of beta-blocker
therapy were independent predictors of death. Among COPD patients,
only older age and hypercapnia predicted a negative outcome.
4. Discussion
Our multicenter observational registry offers insights in the epide-
miology and late clinical course of patients affected by advanced HF or
COPD, which may aid cardiologists and pulmonologists in understand-
ing the turning point from life-prolonging strategies to supportive and
palliative care. Themain ﬁndings of this study are that patients with ad-
vanced HF or COPD represented almost 10% of those accessing hospital
care for these diseases yearly and had overlapping disabling symptoms,
similarly impaired functional status, and comparably reduced survival.
Time spent in hospital during the previous year was themain predictor
of mortality in both patient groups, whereas disease-speciﬁc predictors
of outcome included anemia, low serum sodium, and lack of beta-Table 3
Cox multivariate model for all-cause mortality.
Hazard ratio
(95% CI)
p
value
Overall cohort
Days in hospital during previous year (per unit increase) 1.00 (1.00–1.01) 0.037
Karnofsky performance status (per unit increase) 0.98 (0.96–1.00) 0.06
Medical Research Council dyspnea scale
(per unit increase)
1.30 (0.97–1.75) 0.07
Age (per unit increase) 1.02 (0.99–1.05) 0.13
Gender (male vs female) 1.35 (0.79–2.30) 0.26
Number of comorbidities (per unit increase) 1.08 (0.95–1.24) 0.22
Body mass index (per unit increase) 1.01 (0.96–1.05) 0.78
Heart failure patients
Hemoglobin (per 1 g/dl increase) 0.78 (0.67–0.92) 0.003
Beta-blockers (yes vs no) 0.54 (0.30–0.97) 0.041
Sodium (for each 1 mEq/l increase) 0.94 (0.88–0.99) 0.045
Medical Research Council dyspnea scale
(per unit increase)
1.21 (0.88–1.66) 0.22
Age (per unit increase) 1.02 (0.98–1.04) 0.23
Gender (male vs female) 0.99 (0.52–1.89) 0.98
Chronic obstructive pulmonary disease patients
Age (per unit increase) 1.09 (1.03–1.16) 0.003
PaCO2 (per unit increase) 1.03 (1.00–1.06) 0.052
Gender (male vs female) 1.83 (0.73–4.61) 0.19
BODE index (per unit increase) 1.06 (0.89–1.27) 0.48
Long-term oxygen therapy (yes vs no) 1.42 (0.61–3.27) 0.41
BODE, Body mass index, airway Obstruction, Dyspnea, and Exercise capacity.blocker treatment in HF patients, and older age and hypercapnia in
COPD patients.
This study was planned from the perspective of cardiology and
pulmonology specialist centers, to assess the burden of advanced HF
or COPD to hospital services and to analyze whether speciﬁc criteria
could improve palliative referral of patients with advanced disease
and heavy use of acute hospital services.
In the contemporary literature, data on the prevalence of advanced
HF or COPD stages, according to disease-speciﬁc criteria coupled to se-
verely impaired performance status and high symptom burden, are, to
the best of our knowledge, scanty and not to comparable to ours be-
cause of different study designs [39,40]. Criteria for inclusion in our reg-
istry coupled well-established scales of functional impairment,
commonly used to express disability and the cumulative care burden
in a wide spectrum of illnesses [30,31], to speciﬁc markers of advanced
organ disease [2,3,23]. Indeed the correlation between NYHA class and
Karnofsky performance status has recently been reported to be poor
[41], indicating that for a comprehensive assessment of the care burden
in the daily life, both indexes should be used.
The patients enrolled in our registry represent a sizable proportion
of those requiring acute hospital care each year for HF (7.2%) or COPD
(13%). The prevalence of COPD in patients with HF in the present
hospital-based series is 25.8%,while in previous reports it rangeswidely
from 9 to 52%, depending on the population studied, diagnostic criteria
applied, measurement tools, and surveillance systems [1].
Symptom burden and quality of life impairment of both HF and
COPD patients were similar to previously reported data [5–7,42]. In
our registry the only differences in symptoms are probably linked to
disease-speciﬁc pathophysiology, e.g. COPD patients had a worse dys-
pnea, due to severe chronic hypoxemia, while HF patients complained
more frequently of upper gastrointestinal symptoms, due to splanchnic
congestion.
Within 6 months a comparably high proportion of both groups had
died, the main cause being progression of organ failure. This subset
with high symptoms burden, poor quality of life and short-term poor
outcome represents the ideal group where to concentrate every effort
to reduce the re-hospitalization rate and to implement speciﬁc pro-
grams to palliative care transition in the community. The quest for sim-
ple markers to draw attention on potential candidates to palliative care
is important from an organizational stand point to plan access to often
strained palliatice care services.
Investigations in the natural history of HF have highlighted the very
poor prognosis in advanced stages, with 30 to 50% 1-year mortality [10,
16,21]. Patients who fulﬁlled the enrollment criteria in our study had an
even worse outcome, with a 6 month mortality of 39%, indicating that
they truly had an end-stage condition, where no improvement with
conventional HF treatment is to be reasonably expected and palliative
care should ﬁrst complement and then take the lead of care. In agree-
ment with published data [11–23], disease-speciﬁc predictors of out-
come in our HF series included multiple clinical characteristics, such as
serum sodium concentration, a marker of congestion and neurohor-
monal activation, anemia, a multifactorial comorbidity, and lack of
beta-blocker treatment, expressing drug intolerance as proxy for labile
haemodynamic status, frequently observed in advanced HF. Despite
the high prevalence of COPD, relatively less is known, in comparison
with HF, about the late clinical course of this disease: previous studies
included smallmostly single-center series enrolled after hospital admis-
sion for acute exacerbation [43]. In the early 90's the landmark SUPPORT
study [44] enrolled a cohort of 1016 COPD patients, who had hypercap-
nia at the time of hospital admission for an acute exacerbation: mortal-
ity and readmission rates at 6 months were 33% and 50%, respectively.
In a recent review of relevant studies, a median survival of 2–4 years
was reported for patients with severe COPD, but for those hospitalized
for an exacerbation, median survival may be b6 months, according to
age, functional and clinical characteristics, and repeated hospitalizations
[45].
557A. Gavazzi et al. / International Journal of Cardiology 184 (2015) 552–558Our ﬁndings underscore the poor prognosis of patients with severe
COPD and are in close agreement with data from SUPPORT [44]. Consis-
tently with their advanced disease stage, most patients had severe sys-
temic manifestations, as summarized by an average BODE index of 10,
in the very high risk range: in patients with long standing COPD these
values have been previously associated with 3-year mortality rates of
54.4% [14,46]; therefore, the lack of predictive value that we found in
our series is not surprising. The association with outcome of hypercap-
nia, a common ﬁnding in patients with advanced COPD as a marker of
both severe ventilation–perfusion mismatch and the inability to ade-
quately increase ventilation, is controversial in the overall spectrum of
COPD [15]. Hypercapnia was the only relevant mortality predictor, to-
gether with age, in our COPD patients with severe end-stage disease.
In this respect, home non-invasive ventilation, which was performed
in oneﬁfth of our population,may contribute to symptom relief and im-
prove quality of life [47].
The coexistence of HF and COPD has been reported to exert a nega-
tive synergism on functional status and outcome [1,48], with complex
management problems due to the possible adverse effects of beta-
blockers on airways reactivity, and on the detrimental effects of long-
acting beta2-agonists onheart rate. In the SUPPORT cohort [44], comorbid
HF and cor pulmonale were actually protective against mortality. In our
series, more severe systemic manifestations, but similar functional status
were observed. Moreover, despite a higher number of readmissions, sur-
vival did not differ from patients with either condition alone (Fig. 2).
Overall, patients affected by advanced HF or COPD that enrolled in
our registry show during a short-term follow-up not only the same
negative outcome, but also the same high incidence of prolonged re-
hospitalization, mainly for organ-related failure.
Difﬁcult prognostication in individual patients with advanced HF
and COPD is frequently perceived as an obstacle inhibiting discussions
regarding end of life. The only signiﬁcant predictor by Cox multivariate
analysis in the overall population of the present study was the number
of days in the hospital during the 12 months prior to enrolment. This
ﬁnding highlights the relevance of organ failure-related hospitalizations
as key sentinel events in the late clinical course of patients with either
HF or COPD andmay be used as a screening tool for appropriate referral
to palliative care in the community after discharge. The relevance of this
ﬁnding is that it can be derived from administrative data, allows to rec-
ognize at discharge the patients more prone to a negative outcome and
may be considered as a “red ﬂag”. Patients and caregivers should be
made aware of the likelihood of poor outcomes following repeated hos-
pitalization for exacerbation of organ-related failure. These patients
with high symptom burden, emotional distress, heavy use of acute
care and poor quality of life, stand for almost 10% of subjects hospital-
ized with a primary diagnosis of HF or COPD and represent ideal candi-
dates for a palliative approach. Appropriate programs of palliative care
in the community should be offered to this subset of very ill patients
with non-malignant organ diseases [49], to improve their quality of
life and reduce hospitalization rates, therefore diminishing the econom-
ic burden of end-stage disease [50].Study limitations
The source of data was a multicenter observational registry, where
enrolment was limited to patients with very advanced stages of HF
with reduced ejection or COPD. Outcomes would probably differ in a
larger cohort considering less stringent entry criteria. Among the
seven participating centers, two are large, tertiary referral centers: out-
comesmay change in smaller community hospitals, where themajority
of patients with HF or COPD probably receive a different care. The diag-
nosis of HFwith preserved ejection fraction requires the conﬁrmation of
diastolic dysfunction by Doppler echocardiography, a test which may
not be routinely available, making the differential diagnosis with other
causes of symptoms (e.g. dyspnea) difﬁcult. The exclusion of HFpatientswith preserved ejection fraction from enrolment might have led to the
underestimation of the global palliative care burden for HF.
We did not record data from all patients admitted with decompen-
sated HF or exacerbation of COPD, but only for those meeting the
eligibility criteria for inclusion; therefore, a comparison of mortality
between all patients hospitalized forHF or COPDwasnot possible. How-
ever, our national contemporary data indicate that six-monthmortality
is approximately 20% for patients hospitalized for worsening HF with
reduced ejection fraction in cardiology units [51] and 15% for those
admitted with a severe COPD exacerbation [52].
5. Conclusions
Patients with advanced HF or COPD have overlapping disabling
symptoms, similarly impaired functional status, and comparably re-
duced survival. These very ill patients have a poor quality of life, require
a heavy use of acute care and stand for almost 10% of subjects hospital-
ized with a primary diagnosis of HF or COPD. The length of organ-
related hospitalization during the previous year is the main predictor
of mortality in both groups. This should be considered as a “red ﬂag”
in the late clinical course of patients with HF or COPD and might be
used as a screening tool for appropriate referral after discharge to palli-
ative care in the community.
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Appendix A. Study sites and investigators (all in Italy)
Ospedale Salvini, Garbagnate:Michele Soﬁa, Cristina Arosio, Antonio
Di Leonardo, Vittorio Guardamagna, Roberto Luigi Monticchio, Sergio
Stefano Pardea, Vivian Sardo, Stefano Spagnotto.
Azienda Ospedaliera Ospedale Niguarda-Ca' Granda, Milano: Maria
Frigerio, Enrico Ammirati, Renata De Maria, Maria Grazia Gambato,
Fabrizio Oliva.
Azienda Sociosanitaria 1 Triestina, Trieste: Andrea Di Lenarda, Elena
Abate, Luisa Giove, Franco Humar, Donatella Radini, Marina Riosa, Kira
Stellato.
Ospedale San Luigi Gonzaga, Orbassano: Roberto Pozzi, Marta
Fenoglio, Laura Montagna, Domenico Osella.
Ospedali San Salvatore, Pesaro: Paolo Testarmata, Lucia Cantarini,
Marcello Ugolini.
Ospedali Riuniti di Ancona: Giampiero Perna, Ilaria Battistoni, Martina
Bonifazi, Stefano Gasparini.
AziendaOspedaliera PapaGiovanni XXIII, Bergamo (previousOspedali
Riuniti di Bergamo): Antonello Gavazzi, Marilisa Ambrosio, Anna Cafﬁ,
Marco Marino, Rachele Ramponi, Fausto Svanoni.
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